JP2020519687A5 - - Google Patents

Download PDF

Info

Publication number
JP2020519687A5
JP2020519687A5 JP2020512769A JP2020512769A JP2020519687A5 JP 2020519687 A5 JP2020519687 A5 JP 2020519687A5 JP 2020512769 A JP2020512769 A JP 2020512769A JP 2020512769 A JP2020512769 A JP 2020512769A JP 2020519687 A5 JP2020519687 A5 JP 2020519687A5
Authority
JP
Japan
Prior art keywords
alkyl
substituted
pharmaceutically acceptable
optionally
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020512769A
Other languages
English (en)
Japanese (ja)
Other versions
JP7058322B2 (ja
JP2020519687A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/031593 external-priority patent/WO2018208769A1/en
Publication of JP2020519687A publication Critical patent/JP2020519687A/ja
Publication of JP2020519687A5 publication Critical patent/JP2020519687A5/ja
Application granted granted Critical
Publication of JP7058322B2 publication Critical patent/JP7058322B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020512769A 2017-05-08 2018-05-08 細菌感染症を治療するための化合物および方法 Active JP7058322B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762502867P 2017-05-08 2017-05-08
US62/502,867 2017-05-08
PCT/US2018/031593 WO2018208769A1 (en) 2017-05-08 2018-05-08 Compounds and methods for treating bacterial infections

Publications (3)

Publication Number Publication Date
JP2020519687A JP2020519687A (ja) 2020-07-02
JP2020519687A5 true JP2020519687A5 (https=) 2021-06-10
JP7058322B2 JP7058322B2 (ja) 2022-04-21

Family

ID=62223332

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020512769A Active JP7058322B2 (ja) 2017-05-08 2018-05-08 細菌感染症を治療するための化合物および方法

Country Status (27)

Country Link
US (1) US11046694B2 (https=)
EP (1) EP3630111B1 (https=)
JP (1) JP7058322B2 (https=)
KR (1) KR102611447B1 (https=)
CN (1) CN110709081B (https=)
AU (1) AU2018266640B2 (https=)
CY (1) CY1125340T1 (https=)
DK (1) DK3630111T3 (https=)
EA (1) EA038393B1 (https=)
ES (1) ES2907858T3 (https=)
HR (1) HRP20220231T1 (https=)
HU (1) HUE057592T2 (https=)
IL (1) IL270380B (https=)
LT (1) LT3630111T (https=)
MA (1) MA48743A (https=)
MX (1) MX385203B (https=)
MY (1) MY201377A (https=)
NZ (1) NZ758200A (https=)
PE (1) PE20200333A1 (https=)
PH (1) PH12019502509A1 (https=)
PL (1) PL3630111T3 (https=)
PT (1) PT3630111T (https=)
SG (1) SG11201909443YA (https=)
SI (1) SI3630111T1 (https=)
SM (1) SMT202200110T1 (https=)
TW (1) TWI791018B (https=)
WO (1) WO2018208769A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
EP3833665B1 (en) 2018-08-09 2023-07-19 Antabio SAS Diazabicyclooctanones as inhibitors of serine beta-lactamases
CN111675641B (zh) * 2020-06-04 2023-09-08 宁夏农林科学院农业资源与环境研究所(宁夏土壤与植物营养重点实验室) 单环β-内酰胺类化合物、单环内酰胺类化合物盐及其制备方法
CN115605480B (zh) 2021-05-07 2024-04-05 宁夏农林科学院 磺酰脒取代的化合物及其作为β-内酰胺酶抑制剂的用途
US11814385B2 (en) 2021-06-25 2023-11-14 University Of South Florida Small molecule inhibitors targeting Clostridioides difficile sporulation
AU2024346059A1 (en) * 2023-09-19 2026-04-02 Entasis Therapeutics Inc. Compounds and methods for treating bacterial infections

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ282567B6 (cs) 1993-12-29 1997-08-13 Pfizer Inc. Diazabicyklické sloučeniny a farmaceutické prostředky na jejich bázi
FR2812635B1 (fr) 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
FR2825705B1 (fr) 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
FR2848210B1 (fr) 2002-12-06 2007-10-19 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens et inhibiteurs de beta-lactamases
US7439253B2 (en) * 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors
US7507727B2 (en) * 2003-04-07 2009-03-24 Cylene Pharmaceuticals, Inc. Substituted quinobenzoxazine analogs and methods of using thereof
FR2914923B1 (fr) 2007-04-12 2013-06-14 Novexel Nouveaux composes heterocycliques azotes,leur preparation et leur utilisation comme medicaments antibacteriens.
WO2009091856A2 (en) 2008-01-18 2009-07-23 Merck & Co., Inc. Beta-lactamase inhibitors
FR2930553B1 (fr) 2008-04-29 2010-05-21 Novexel Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment inhibiteurs de beta-lactamases
EP2921559A1 (en) 2008-06-19 2015-09-23 Astra Zeneca Holding France Use of (1r,2s,5r) 1,6-diazabicyclo [3.2.1]octane-2-carboxamide, 7-oxo-6-(sulfooxy)-, monosodium salt as a diagnostic reagent for detecting serine beta-lactamases
FR2936798B1 (fr) 2008-10-03 2012-09-28 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens.
FR2937034B1 (fr) * 2008-10-10 2012-11-23 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens
FR2936951B1 (fr) 2008-10-10 2010-12-03 Novexel Nouvelles combinaisons de composes heterocycliques azotes antibacteriens avec d'autres composes antibacteriens et leur utilisation comme medicaments
FR2951171A1 (fr) 2009-10-09 2011-04-15 Novexel Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
WO2013014497A1 (en) 2011-07-26 2013-01-31 Wockhardt Limited Pharmaceutical compositions comprising beta-lactam antibiotic, sulbactam and beta-lactamase inhibitor
NZ616806A (en) 2011-07-26 2015-03-27 Wockhardt Ltd Pharmaceutical compositions comprising sulbactam and beta-lactamase inhibitor
MX348974B (es) 2011-08-27 2017-07-04 Wockhardt Ltd Derivados 1,6 - diazabiciclo [3,2,1] octan-7-ona y su uso en el tratamiento de infecciones bacterianas.
CA2845108C (en) * 2011-08-30 2015-06-16 Wockhardt Limited 1,6-diazabicyclo[3,2,1]octan-7-one derivatives and their use in the treatment of bacterial infections
CA2846107C (en) 2011-09-13 2016-06-21 Wockhardt Limited Nitrogen containing compounds and their use
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
EP2814483A2 (en) 2012-02-15 2014-12-24 Rempex Pharmaceuticals, Inc. Methods of treating bacterial infections
WO2013149136A1 (en) 2012-03-30 2013-10-03 Cubist Pharmaceuticals, Inc. ISOXAZOLE β-LACTAMASE INHIBITORS
US8969570B2 (en) 2012-03-30 2015-03-03 Cubist Pharmaceuticals, Inc. Beta-lactamase inhibitors
US8916709B2 (en) 2012-03-30 2014-12-23 Cubist Pharmaceuticals, Inc. 1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors
US8940897B2 (en) 2012-03-30 2015-01-27 Cubist Pharmaceuticals, Inc. 1,3,4-oxadiazole and 1,3,4-thiadiazole β-lactamase inhibitors
AR090539A1 (es) * 2012-04-02 2014-11-19 Astrazeneca Ab COMPUESTOS INHIBIDORES DE b LACTAMASA
HUE046893T2 (hu) 2012-05-30 2020-04-28 Meiji Seika Pharma Co Ltd Új ß-laktamáz inhibitor és eljárás elõállítására
RU2614418C2 (ru) 2012-08-25 2017-03-28 Вокхардт Лимитед Производные 1,6-диазабицикло[3.2.1]октан-7-она и их применение для лечения бактериальных инфекций
US20150258072A1 (en) 2012-09-03 2015-09-17 Wockhardt Limited Antibacterial compositions
EP2953626A1 (en) 2013-02-06 2015-12-16 Astrazeneca AB Combination therapy for the treatment of nosocomial pneumonia
WO2014141132A1 (en) * 2013-03-14 2014-09-18 Naeja Pharmaceutical Inc. NEW HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS
JP6764862B2 (ja) 2014-11-17 2020-10-07 エンタシス・セラピューティックス・リミテッド 耐性細菌感染症の治療のための併用療法
DK3512851T3 (en) 2016-09-16 2022-10-17 Entasis Therapeutics Ltd Beta-lactamase inhibitor compounds

Similar Documents

Publication Publication Date Title
JP2020519687A5 (https=)
JP2019513778A5 (https=)
JP2014525420A5 (https=)
JP2016506960A5 (https=)
JP2016506958A5 (https=)
JP2013544276A5 (https=)
JP2018524390A5 (https=)
JP2016503799A5 (https=)
JP2021522166A5 (https=)
JP2016506962A5 (https=)
JP2009534386A5 (https=)
JP2010511721A5 (https=)
JP2016505586A5 (https=)
JP2016515561A5 (https=)
JP2018516904A5 (https=)
JP2016507575A5 (https=)
JP2020097577A5 (https=)
JP2013531029A5 (https=)
JP2018524406A5 (https=)
JP2007524696A5 (https=)
JP2012513416A5 (https=)
JP2010527913A5 (https=)
JP2015504081A5 (https=)
JP2014510147A5 (https=)
JP2020122016A5 (https=)